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Abstract—Hypertensive disorders of pregnancy (HDP) are associated with low birth weight, shorter gestational age, 
and increased risk of maternal and offspring cardiovascular diseases later in life. The mechanisms involved are 
poorly understood, but epigenetic regulation of gene expression may play a part. We performed meta-analyses in the 
Pregnancy and Childhood Epigenetics Consortium to test the association between either maternal HDP (10 cohorts; 
n=5242 [cases=476]) or preeclampsia (3 cohorts; n=2219 [cases=135]) and epigenome-wide DNA methylation in cord 
blood using the Illumina HumanMethylation450 BeadChip. In models adjusted for confounders, and with Bonferroni 
correction, HDP and preeclampsia were associated with DNA methylation at 43 and 26 CpG sites, respectively. HDP was 
associated with higher methylation at 27 (63%) of the 43 sites, and across all 43 sites, the mean absolute difference in 
methylation was between 0.6% and 2.6%. Epigenome-wide associations of HDP with offspring DNA methylation were 
modestly consistent with the equivalent epigenome-wide associations of preeclampsia with offspring DNA methylation 
(R2=0.26). In longitudinal analyses conducted in 1 study (n=108 HDP cases; 550 controls), there were similar changes in 
DNA methylation in offspring of those with and without HDP up to adolescence. Pathway analysis suggested that genes 
located at/near HDP-associated sites may be involved in developmental, embryogenesis, or neurological pathways. HDP 
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Hypertensive disorders of pregnancy (HDP), including gestational hypertension (GH) and preeclampsia, are 
among the most common complications of pregnancy.1 
Previous studies have found associations between maternal 
HDP and the hematological profile of newborns,2 preterm 
birth,3 low birth weight,4 and slower growth patterns in early 
infancy.5 Associations of HDP with subsequent higher blood 
pressure (BP) and cardiovascular disease risk in offspring 
have also been reported.6–8 The mechanisms underlying these 
associations are not fully understood. It has been suggested 
that environmentally responsive, mitotically stable epigenetic 
phenomena, such as DNA methylation, may mediate some 
of the impact of intrauterine exposures, such as to maternal 
HDP, on subsequent health outcomes in offspring.9
Several small studies have found preeclampsia-associated 
differences in DNA methylation, other epigenetic markers, 
and gene expression in placental tissue,10–14 maternal gesta-
tional blood cells, and maternal omental fat biopsies collected 
during gestation.15,16 Two previous studies have explored the 
association of HDP with DNA methylation in offspring cord 
blood.17,18 Previous studies included small number of pree-
clampsia cases, reported few findings that reached genome-
wide level of confidence, and findings were not replicated. 
Larger studies would enable replication of these findings to be 
tested and would likely identify novel loci.
We hypothesized that HDP may influence DNA methyla-
tion patterns in cord blood in genes that are important for fetal 
development. To address this, we examined the association of 
HDP (preeclampsia and GH jointly), with epigenome-wide 
DNA methylation in cord blood by meta-analyzing results from 
10 birth cohorts from the pregnancy and childhood epigenetics 
consortium. Our main analyses focused on HDP, and in ad-
ditional analyses, we also explored epigenome-wide differen-
tial methylation between cases of preeclampsia and controls 
(without any form of HDP). We performed pathway analyses 
to explore the underlying biology of differentially DNA meth-
ylated sites for HDP and preeclampsia.19 We also investigated 
whether the differentially methylated CpG sites (CpGs) identi-
fied in relation to HDP in cord blood change over time in se-
rial samples taken from the same individuals in childhood and 
adolescence (as well as cord blood) using data from 1 cohort.
Methods
Data Availability
Data supporting the results reported in this article can be found in the 
online-only Data Supplement. We are unable to make individual-level 
data available because of concerns about compromising individual 
privacy; however, data used in these analyses are available from the 
individual cohorts on request. Full meta-analysis results datasets 
generated in this study are available from the corresponding author 
(nabila.kazmi@bristol.ac.uk) on request.
Cohort Participants
Our a priori primary analysis was of the association of HDP with 
epigenome-wide DNA methylation in cord blood. This provided 
maximal statistical power by enabling us to include all studies, in-
cluding those that did not have sufficient numbers of preeclampsia for 
meaningful analyses or had not collected data that could differentiate 
GH from preeclampsia. In secondary analyses, we examined associa-
tions of preeclampsia only with DNA methylation in cord blood.
All pregnancy and childhood epigenetics consortium studies were 
invited to participate, women had to have experienced a singleton 
pregnancy, and only those studies with >10 cases of HDP were in-
cluded in the main analyses. Similarly, for the secondary analyses of 
preeclampsia, only studies with >10 cases of preeclampsia occurring 
in singleton pregnancies were included.
Ten cohorts were included in the meta-analysis of HDP and cord 
blood methylation. These cohorts listed in alphabetic order were 
the following: the ALSPAC (Avon Longitudinal Study of Parents 
and Children),20–22 the GenR (Generation R) study,23,24 the GOYA 
(Genetics of Overweight Young Adults) study (a genome-wide pop-
ulation-based association study nested in the Danish National Birth 
Cohort),25,26 healthy start (Hispanic and non-Hispanic),27,28 the Isle of 
Wight cohort,29 2 independent datasets from the MoBa (Norwegian 
Mother and Child Cohort Study; MoBa1 and MoBa2),30,31 The 
PREDO (Prediction and Prevention of Preeclampsia and Intrauterine 
Growth Restriction),32 and Project Viva.33
MoBa (MoBa1 and MoBa2) and PREDO also had sufficient num-
ber of cases (n>10) to contribute to the meta-analysis of the specific 
association of preeclampsia with cord blood DNA methylation.
Meta-Analyses
We used inverse variance-weighted fixed effects meta-analysis per-
formed in METAL34 to pool results across studies. This method sum-
marizes effect sizes from several independent studies by calculating 
the weighted mean of the effect sizes using the inverse variance of the 
individual studies as weights.35 A fixed-effect meta-analysis assumes 
that all studies are from the same underlying population, and the 
pooled results reflect the association in that population. We a priori 
assumed that the studies contributing to this collaboration were from 
the same underlying population. However, we explored heterogeneity 
between studies for adjusted results that reached our prespecified 
Bonferroni level of statistical significance using Cochran Q statistic 
and by undertaking leave-one-out analyses; the latter using metafor 
in the R statistical package.36 These analyses test our assumption that 
results are from the same underlying population and act as a test of 
replication. If results are consistent across studies (ie, the Q test sup-
ports the null hypothesis of no heterogeneity, and results of meta-anal-
yses that remove one of the studies at a time are consistent with each 
other), this shows replication across the different studies included in 
our meta-analysis. We considered the fully adjusted models (adjusted 
for confounders, cell proportions, and technical covariates [batch 
effects]37; each cohort adjusted for technical covariates using meth-
ods suitable for that cohort [online-only Data Supplement]) as our 
primary analyses but also reported the results of an unadjusted model. 
The sample size was the same for adjusted and unadjusted models: 
HDP (n=5242, cases=476) and preeclampsia (n=2219, cases=105). 
We highlighted results from the meta-analysis that reached statistical 
significance based on a false discovery rate of 5% and also with a more 
stringent Bonferroni-corrected P threshold (P<1.05×10−7; correcting 
for 475 089 tests for HDP analysis and 473 862 tests for preeclampsia 
analysis). The CpGs passing the more stringent Bonferroni-corrected 
P were considered our primary findings.
Differentially Methylated Region Analysis
In addition to EWAS (epigenome-wide association study) analy-
ses, differentially methylated region (DMR) analyses in relation to 
HDP and preeclampsia were conducted separately using the R pack-
age DMRcate.38 In the DMR analysis, the results of fully adjusted 
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meta-analyzed models were used. DMRcate groups associated 
probes into separate DMRs if the gap between nucleotides is ≥1000 
base pairs and the Bonferroni-corrected P of associations <0.05.
Longitudinal Analysis of HDP and Offspring 
Methylation
Longitudinal analyses were performed to examine whether the asso-
ciations of HDP on offspring differential DNA methylation at CpGs 
at birth were observed at the same CpGs in blood cells at age ≈7 
years (mean age, 7.5 years; SD, 0.1) and at age ≈17 years (mean 
age, 17.1 years; SD, 1.0). These analyses were conducted in 1 co-
hort only (ALSPAC) and were restricted to the Bonferroni signifi-
cant CpGs from the main HDP EWAS. Multilevel models were used, 
level 1 being the repeat assessments (at birth, 7 years, or 17 years) 
and within participants (level 2).39,40 The CpGs were first linked to 
the gene symbols using an Illumina mapping file and if unsuccessful 
were annotated to the nearest gene within 10 Mb of each CpG. A mul-
tilevel model including a random intercept (to allow for between in-
dividual variability in methylation) and a linear spline term (to allow 
for nonlinear change in methylation from birth to 17 years) was fitted 
to each of these CpGs. This model is described in more detail in the 
online-only Data Supplement. These longitudinal analyses included 
658 participants in whom 108 had been exposed to HDP.
Additional Information
Additional information (definition of HDP, covariates, methylation 
measurements and quality control, estimation of cell-type propor-
tions, CpG annotation, statistical analysis methods, and some results) 
is provided in online-only Data Supplement.
Results
Study Characteristics
A total of 10 independent cohorts participated in our meta-
analysis of HDP and DNA methylation of cord blood. The total 
number of newborns was 5242, including 476 whose mothers 
met our criteria for HDP (cases of GH+preeclampsia). Of those 
10 cohorts, 3 contributed to the preeclampsia analyses (n=135 
cases; Table 1). Each cohort is described in detail in Table S1.
Main Meta-Analyses Results
In the EWAS meta-analysis evaluating the association between 
HDP and differential DNA methylation in cord blood, after ad-
justment for confounders, estimated cell counts, and technical 
covariates, we found 43 differentially methylated sites that 
passed the Bonferroni-corrected P (P<1.05×10–7) threshold 
(Figure; Table 2; Table S2). HDPs were associated with higher 
methylation levels at 27 (63%) of the CpGs, and across all 
CpGs, associations were relatively weak with the range of 
mean difference in methylation being 0.6% to 2.6%. In unad-
justed meta-analysis of the association of HDP with cord blood 
DNA methylation, 70 CpGs reached the Bonferroni P (Table 
S3) including 12 of the 43 CpGs identified in adjusted analyses. 
When we directly compared the direction and size of associ-
ation in the 2 EWAS of HDP (unadjusted EWAS versus fully 
adjusted EWAS), we found moderate consistency between the 
two (R2=0.48, slope=0.854±0.001; Figure S1). When we used a 
5% false discovery rate method to account for multiple testing 
(rather than Bonferroni correction), a much larger number of 
CpGs (n=1075) were shown to be differentially methylated in 
relation to HDP in the fully adjusted model (Figure; Table S2).
In the EWAS meta-analysis evaluating the association be-
tween preeclampsia and differential DNA methylation in cord 
blood after adjustment for confounders, estimated cell counts, 
and technical covariates, we found 26 differentially methyl-
ated sites passed the Bonferroni-corrected P (P<1.05×10–7) 
threshold (Figure S2; Table S4). Preeclampsia was associated 
with higher methylation levels at 23 (88%) of the CpGs, and 
across all CpGs, associations were somewhat stronger than 
HDP associations, with the range of mean difference in meth-
ylation being 1.1% to 4.4%. In unadjusted meta-analysis of 
the association of preeclampsia with cord blood DNA meth-
ylation, 117 CpGs reached the Bonferroni P (Table S5), in-
cluding 12 of the 24 identified in the adjusted analyses. When 
we directly compared the direction and size of association in 
the 2 EWAS of preeclampsia (unadjusted EWAS versus fully 
adjusted EWAS), we found moderately strong consistency 
(R2=0.41, slope=0.918±0.002; Figure S3). When we used a 
5% false discovery rate method to account for multiple test-
ing (rather than Bonferroni correction), a much larger number 
of CpGs (n=542) were differentially methylated in relation to 
preeclampsia in the fully adjusted model (Figure S2; Table S4).
The genomic inflation factor, λ, for all HDP and pree-
clampsia models is provided in (Tables S6 and S7, respectively). 
λ-Values for preeclampsia were higher than the meta-analysis 
results for HDP, likely because of smaller number of pree-
clampsia cases. Five of the differentially methylated sites for 
preeclampsia were also identified in the Bonferroni-corrected 
analyses for HDP. When we directly compared the association 
direction and sizes of the 2 EWAS (EWAS of HDP and EWAS 
of preeclampsia), we found modest consistency between the 
two (R2=0.26, slope=1.17±0.003; Figure S4).
There was some statistical evidence of between study 
heterogeneity for one of the 43 HDP-related CpGs at a strin-
gent Bonferroni-corrected Cochrane Q P (P<0.001) threshold 
(Table S2). For the preeclampsia EWAS, there was no evidence 
of interstudy heterogeneity for all 26 CpGs at Bonferroni-
corrected Cochrane Q P threshold of 0.002 (Table S4). The 
results of leave-one-out analysis illustrated that no single co-
hort had a disproportionally large influence on the meta-analy-
sis results, and most cohorts agreed on the direction of effect at 
the CpGs that surpassed the Bonferroni significance (Figures 
S5 and S6). We compared our EWAS results of HDP and pree-
clampsia to previously published EWAS of early onset of pree-
clampsia (EOPE) in cord blood of offspring.17 Ten of the 43 and 
7 of the 26 CpGs that were found in the meta-analysis results 
of HDP and preeclampsia, respectively, were previously re-
ported in relation to EOPE (Tables S2 and S4). All these CpGs 
showed the same direction of association in both studies.
Epidemiological studies have suggested that the off-
spring of mothers with HDP/preeclampsia have a higher risk 
of long-term hypertension.6,42 An EWAS of systolic BP and 
diastolic BP was conducted among individuals of European, 
black, and Hispanic/Latino ancestry (n=17 101).43 We com-
pared our EWAS results of HDP and preeclampsia to this 
previously reported EWAS but did not find any overlap. 
We also compared our EWAS results to those previously 
reported in cord blood EWAS of birth weight44 and gesta-
tional age.45 Three CpGs related to HDP in our analysis have 
been previously shown to be differentially methylated in 
cord blood in relation to birth weight,44 with opposite direc-
tions of association compared with the direction we found 
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for HDP (ie, where HDP associates with lower methylation 
levels and higher birth weight associates with higher meth-
ylation levels; Table S8; Figure S7A). These findings sug-
gest that the known association of HDP with lower birth 
weight may be mediated through DNA methylation at these 
CpGs. Additionally, 19 of the 43 CpGs we identified in our 
HDP EWAS have been previously shown to be differentially 
methylated in cord blood in association with gestational 
age45 (Table S9; Figure S7B). Again, the direction of asso-
ciation estimated for HDP was opposite to that estimated 
for gestational age, suggesting that the association between 
HDP and lower gestational age might be mediated through 
DNA methylation.
Pathway analyses were performed using top CpGs iden-
tified in the meta-analyses results for enrichment of certain 
gene ontology terms or biologic pathways. The HDP pathway 
analysis identified several categories of biologic processes 
including organ and system development, regulation of cell 
communication, and cell differentiation. The details are pro-
vided in online-only Data Supplement.
DMR Analysis
DMR analyses were performed to identify associations of HDP 
and preeclampsia with regions of DNA methylation in cord 
blood. DMR analysis identified HDP associating with 248 re-
gions (annotated to 203 genes) and preeclampsia associating 
with 185 regions (annotated to 164 genes) with adjustment for 
confounders and white cell counts at Bonferroni-corrected P 
(Tables S10 and S11).
In a comparison to EWAS analyses, 30 of the 39 unique 
genes annotated to HDP-associated CpGs, overlapped with 
genes identified in DMR analysis of HDP (Table S12). 
Similarly, 24 genes of the 25 unique genes annotated to pre-
eclampsia-associated CpGs overlapped with the results of 
DMR analysis of preeclampsia (Table S13).
Longitudinal Analysis of HDP and Offspring 
Methylation
Longitudinal mixed-model analyses were undertaken in a 
subset of the ALSPAC cohort (n=108 HDP cases and 550 
controls). As an illustration of the general pattern of observed 
Table 1. Summary of Cohorts Participating in the Meta-Analysis of HDP and DNA Methylation at Birth
Cohort n
No. of HDP 
Cases/No. 
of Controls
No. of PE 
Cases/No. 
of Controls
Maternal 
Age, y; 
Mean (SD)
Parity ≥1, 
n (%)
Smoking 
During 
Pregnancy, 
n (%)
Preexisting 
or 
Gestational 
Diabetes 
Mellitus, n 
(%)
Maternal 
BMI, Mean 
(SD)
Female 
Infant, n 
(%) Ethnicity
Gestational 
Age, wk; 
Mean (SD)
Birth 
Weight, 
g; Median 
(IQR)
ALSPAC 658 108/550 10/550* 29.9 (4.3) 360 (55%) 82 (12%) 26 (4%) 22.7 (3.4) 344 (52%) European 40.0 (2) 3500 (600)
GenR 838 54/784 NA* 31.5 (4.2) 342 (39%) 210 (25%) Not 
included
24.3 (4.0) 400 (48%) European 40.3 (1.7) 3556 (500)
GOYA 540 17/523 10/523* 29.1 (4) 504 (93%) 215 (40%) 0 29.2 (3.9) 272 (50%) European 40.4 (1.9) 3677.5 (646)
HS (Hispanic) 135 11/124 NA* 24.86 (5.9) 64 (47%) 31 (23%) 8 (6%) 28.09 (7.7) 66 (49%) Hispanic 39.4 (1.6) 3309 (405)
HS (non-
Hispanic)
301 28/273 10/273* 30.03 (5.2) 125 (41%) 93 (31%) 14 (5%) 24.70 (5.3) 142 (47%) Non-
Hispanic 
white 
European
39.7 (1.4) 3330 (439)
IOW 124 11/113 NA* 23.24 (2.5) 50 (40%) 46 (37%) Not 
included
27.28 (6.2) 64 (52%) European 40.0 (2.0) 3427.4 
(519.0)
MoBa1 1020 52/968 32/968 29.9 (4.3) 600 (59%) 287 (28%) 16 (1.6%) 24.0 (4.2) 474 (46%) European 40.1 (1.9) 3644.0 
(545.6)
MoBa2 644 37/607 29/607 30.0 (4.5) 384 (60%) 162 (25%) 7 (1%) 24.2 (4.5) 282 (44%) European 40.1 (2.0) 3661 (537)
PREDO 663 124/539 44/539 33.06 (5.9) 472 (71%) 28 (4%) 149 (22%) 26.94 (6.2) 309 (47%) European 40.0 (1.86) 3580 (546)
Project viva 319 34/285 NA* 33.2 (4.4) 168 (53%) 28 (9%) 15 (5%) 24.0 (4.4) 161 (50%) Non-
Hispanic 
white 
European
39.8 (1.5) 3609 (488)
Meta-
analysis
5242 
(2219 
for PE)
476/4766 135/3460 … … … … … … … … …
ALSPAC indicates Avon Longitudinal Study of Parents and Children; BMI, body mass index; EWAS, epigenome-wide association study; GenR, Generation R; GOYA, 
Genetics of Overweight Young Adults; HDP, hypertensive disorders of pregnancy; HS, healthy start; IOW, Isle of Wight; IQR, interquartile range; MoBa, Norwegian Mother 
and Child Cohort Study; NA, not assessed separately from HDP; PE, preeclampsia; and PREDO, Prediction and Prevention of Preeclampsia and Intrauterine Growth 
Restriction.
*These studies did not contribute to the analyses of associations of PE with cord blood DNA methylation because they had ≤10 cases (or it was not possible to identify 
PE cases); therefore, the total numbers in the PE analyses are 105 cases and 2114 controls. GenR and IOW ran EWAS without including preexisting or gestational 
diabetes mellitus. GenR found convergence issues because of low number of cases, and the information about preexisting or gestational diabetes mellitus is not 
available for IOW.
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results, Figure S8 shows longitudinal changes in methylation 
for the top 4 CpGs reached Bonferroni-corrected P threshold 
in the main adjusted HDP cord blood EWAS meta-analysis (all 
results are provided in Table S14). There were similar increases 
in methylation levels between birth and adolescence for most of 
the 43 CpGs in offspring of mothers who experienced HDP and 
those who did not. For a small number of CpGs, this age-related 
change was weaker and less consistent between 7 and 17 than 
between birth and 7 years. For all but 1 of the 43 CpGs, there 
was no strong statistical evidence that age-related change dif-
fered between offspring of cases and controls, suggesting that 
differences persisted but that this was because of general age-
related change rather than any further long-term effect of expo-
sure to HDP in utero. For the CpG cg08274637 (near DLEU7 
gene), there was evidence that offspring of HDP mothers (com-
pared with those whose mothers who did not experience HDP) 
had a slightly faster increase in methylation between birth and 
age 7 (0.27% increased methylation change per year; 95% CI, 
0.13%–0.41% methylation change per year; P=0.0002).
Discussion
In this study, we found that HDP (including GH and pree-
clampsia) and preeclampsia alone are associated with multiple 
epigenetic methylation marks in cord blood. In our meta-
analyses, HDP and preeclampsia were associated with both 
increased and reduced methylation with generally small mean 
differences. There were only modest levels of consistency in 
the magnitude and direction of associations between the pre-
eclampsia and HDP EWAS results, suggesting that overall 
DNA methylation patterns in offspring cord blood may differ 
between preeclampsia and GH. However, we acknowledge that 
for preeclampsia analyses, only 3 independent studies contrib-
uted and the overall sample size was small. A previous study 
examined the association of EOPE with DNA methylation in 
offspring cord blood using 12 cases of EOPE compared with 
8 controls.17 There was a small overlap between the results of 
EWAS of our study and previously reported EWAS of EOPE.17 
As EOPE is a different outcome to our outcomes and this pre-
vious study is smaller than ours, we might not anticipate sub-
stantial overlap. A previous study reported the association of 
systolic BP and diastolic BP with DNA methylation in blood. 
There was no overlap seen between the results of cord blood 
EWAS of HDP/preeclampsia exposure from our study and the 
previous adult blood EWAS and cross-sectional association 
with BP. Hypertension is a multifactorial disease involving 
multiple genetical and environmental factors and is medi-
ated by alterations in multiple biologic pathways. The lack of 
overlap between studies may be related to that prior findings 
of methylation levels in adult blood may be consequences of 
elevated BP or lifestyle leading to both change in methylation 
and high BP, while our findings may reflect developmental im-
pact of prenatal exposure to maternal hypertensive conditions.
Figure. A Manhattan plot indicating the association between hypertensive disorders of pregnancy and cord blood DNA methylation in a meta-analysis. The 
model was adjusted for confounders; maternal age (years), parity (nulliparous vs multiparous), maternal smoking status (no smoking in pregnancy, stopped 
smoking in early pregnancy, smoking throughout pregnancy), diabetes mellitus (no preexisting or gestational diabetes mellitus vs prepregnancy or gestational 
diabetes mellitus), maternal prepregnancy body mass index (kg/m2), and child sex. The model was also adjusted for estimated cell counts and technical 
covariates. The uncorrected −log10(P) are plotted. A total of 1075 CpG sites (CpGs) reached the false discovery rate threshold (blue line) and 43 CpGs 
surpassed the Bonferroni threshold (red line).
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Table 2. Associations Between HDP and Cord Blood DNA Methylation Levels at CpGs That Surpassed the Bonferroni Significance Threshold (Adjusted for Confounders, 
Cell-Type Proportions, and Technical Covariates)
CHR Position CpG
Mapped 
Gene Nearest Gene Gene Group Coefficient SE P Value Direction Cochrane Q
1 54100163 cg09007354 GLIS1 GLIS1 5′UTR −0.0097 0.0017 3.11×10−8 −−−?−−−−−+ 0.3862
1 55353706 cg17901584 DHCR24 HP08874 TSS1500 0.0137 0.0024 7.27×10−9 +++?++++−+ 0.1477
1 147789973 cg10537450  TRNA_Pseudo  −0.0106 0.0019 3.19×10−8 −?−−−−−−−− 0.7104
1 183516266 cg13492133 SMG7 SMG7 Body −0.0159 0.003 8.06×10−8 −−−+−−−−−+ 0.2139
2 21264562 cg21319310* APOB APOB Body 0.0089 0.0016 1.51×10−8 +?+−+−+−++ 0.04003
3 12858887 cg23482898 CAND2 CAND2 Body 0.0088 0.0015 1.32×10−8 ++−−++++++ 0.2888
3 12858926 cg11882607 CAND2 CAND2 Body 0.012 0.002 1.49×10−9 +++−++++++ 0.371
3 12996362 cg25157472 IQSEC1 IQSEC1 Body 0.0098 0.0018 2.58×10−8 −++−++++++ 0.09851
3 49692537 cg24296397 BSN BSN Body 0.0121 0.0021 1.16×10−8 +++−+++++− 0.2612
3 123371420 cg07638500* MYLK MYLK Body −0.0137 0.0022 3.12×10−10 −−−?−−−−−+ 0.1834
3 155422129 cg11932158* PLCH1 PLCH1 TSS200 0.0175 0.0031 2.64×10−8 +++−+++++− 0.3577
3 183749227 cg14483391 HTR3D HTR3D TSS1500; TSS200 −0.0125 0.0023 4.24×10−8 +−−?−−−−−− 0.009811
4 166251189 cg05119988 SC4MOL MSMO1 5′UTR 0.016 0.003 6.26×10−8 ++++++++++ 0.33
5 6766613 cg12970171  PAPD7  0.0109 0.002 6.13×10−8 +++−+++++− 0.07992
5 131409289 cg02325250 CSF2 CSF2 TSS200 0.0101 0.0017 6.72×10−9 +++−++++++ 0.413
5 151051214 cg10505630 SPARC SPARC Body 0.0091 0.0015 5.64×10−10 +++?++++−+ 0.282
6 149775853 cg04494800 ZC3H12D ZC3H12D Body 0.0124 0.0023 6.83×10−8 +++−++++−+ 0.2698
9 124584474 cg13622265* TTLL11 TTLL11 3′UTR −0.0173 0.0031 1.82×10−8 −−−?−−−−−− 0.3175
10 4117248 cg25124943  AK055803  0.012 0.0021 6.92×10−9 +++−++++++ 0.7748
10 63753550 cg25953130 ARID5B JA660620 Body 0.0215 0.004 7.21×10−8 +++−++++++ 0.1759
10 125780810 cg24186506 CHST15 CHST15 Body −0.0174 0.0032 3.61×10−8 −−−?−−−−−− 0.7025
11 36422615 cg08943494* PRR5L PRR5L 5′UTR; first exon; body 0.0279 0.0047 4.35×10−9 +++−++++++ 0.309
11 46709238 cg27652459 ARHGAP1 ARHGAP1 Body 0.0096 0.0017 7.11×10−9 +++−++++++ 0.5665
12 114297307 cg03546806 RBM19 RBM19 Body −0.0141 0.0023 4.73×10−10 −−−?−−−−−+ 5.11×10−5
12 124985889 cg20494738 NCOR2 NCOR2 5′UTR −0.0074 0.0013 3.40×10−8 −−−−−−−−−+ 0.3591
13 51417923 cg08274637* DLEU7 DLEU7 TSS200 −0.0136 0.0024 1.40×10−8 −−−?−−−−−− 0.3019
13 51417929 cg13846270* DLEU7 DLEU7 TSS200 −0.0106 0.002 8.10×10−8 −−−+−−−+−− 0.1399
13 51417977 cg27051129* DLEU7 DLEU7 TSS200 −0.0106 0.002 9.04×10−8 −−−−−−−−+− 0.1799
13 99218287 cg01185345 STK24 STK24 Body 0.0086 0.0016 4.23×10−8 +++−++++++ 0.2207
13 114302021 cg12212198  ATP4B  0.0088 0.0015 8.53×10−9 +?+?+++−−+ 0.01268
14 22902226 cg27295118  AK125397  0.0198 0.0037 8.48×10−8 ++++++++++ 0.328
15 74532450 cg02430430 CCDC33 CCDC33 Body 0.0129 0.0023 2.84×10−8 +++−++++++ 0.1286
16 2087932 cg09476997 SLC9A3R2 SLC9A3R2 Body −0.0261 0.0037 1.86×10−12 −−−?−−−−−+ 0.3117
16 16116191 cg04730825 ABCC1 ABCC1 Body 0.0119 0.0022 7.83×10−8 −++?++++++ 0.2254
17 37331531 cg26128121 CACNB1 CACNB1 Body −0.0114 0.0021 2.90×10−8 −−−?−−−−−− 0.915
17 38470900 cg25362050* RARA RARA 5′UTR 0.0092 0.0014 1.75×10−10 +++?++++++ 0.1782
17 47076904 cg18183624* IGF2BP1 IGF2BP1 Body −0.0209 0.0035 3.70×10−9 −−−−−−−−−− 0.0163
17 47077165 cg07738730* IGF2BP1 IGF2BP1 Body −0.0199 0.0029 1.06×10−11 −−−−−−−−−− 0.001224
19 940967 cg02001279 ARID3A ARID3A Body 0.0147 0.0023 1.72×10−10 +++++++++− 0.4358
19 1126342 cg07573872 SBNO2 SBNO2 Body 0.0098 0.0017 1.60×10−8 +−+?++++−+ 0.00259
19 1614570 cg07562120 TCF3 TCF3 Body −0.0068 0.0012 6.75×10−9 +−−−−−−−−+ 0.3149
(Continued )
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The DMR analyses of HDP and preeclampsia identified a 
region that was annotated to AVP gene. Arginine vasopressin 
is essential for both osmotic and cardiovascular homeostasis 
and exerts important physiological regulation through 3 recep-
tors, V1a, V1b, and V2.46 Results of animal study showed that 
the V1a receptor has an important role in normal resting ar-
terial BP regulation mainly by regulating circulating blood 
volume and through baroreflex sensitivity.46 Arginine vaso-
pressin has also been previously associated with congestive 
heart failure.47
HDP and a higher maternal BP across pregnancy are asso-
ciated with small for gestational age, low birth weight, and a 
shorter gestation.48–50 We did not adjust our main analyses for 
gestational age or birth weight as these could not plausibly influ-
ence HDP (and so could not confound the association) but may 
be on a causal path between HDP and its treatment (including 
early delivery) and cord blood DNA methylation. In support of 
this, Mendelian randomization analyses suggest a causal inverse 
effect of maternal BP on birth weight.51 In this study, we found 
evidence of overlap between results for differential DNA meth-
ylation in cord blood related to HDP and CpGs that have been 
shown to be related to birth weight44 or gestational age45 that di-
rectionally would support potential epigenetic mediation of any 
effect of HDP on birth weight and gestational age.
Although we postulate that DNA methylation lies on 
a causal pathway between HDP and birth weight, we can-
not discount the possibility that HDP is exerting effects on 
DNA methylation and birth weight/gestational age or that the 
associations we have observed are explained by residual con-
founding. Additional analyses, such as Mendelian randomi-
zation, could help to elucidate causal effects,52 but we were 
unable to use Mendelian randomization in this study because 
of the lack of available maternal genetic instruments specific 
for HDP. Longitudinal analyses suggested that DNA methyla-
tion levels increased with age across most of the HDP-related 
CpGs but that this was similar in offspring of mothers with 
and without HDP. These findings suggest that the association 
of HDP with differential methylation in cord blood remains, 
but there is no further effect (beyond what is seen at birth) of 
HDP on differential DNA methylation at these CpGs. These 
longitudinal analyses were conducted in just 1 study, with 
no possibility to explore replication, and had limited power. 
We cannot exclude the possibility that we had larger num-
bers of studies and participants and more repeat measures of 
epigenome-wide data, we might have identified an effect of 
HDP on age-related DNA methylation change. Difference in 
DNA methylation observed at birth may still influence health 
at older ages through a transient influence on gene expression.
To assess the underlying biology involved in the asso-
ciated genomic regions, we performed pathway analyses. 
These results implicated developmental, embryogenesis, and 
neurological pathways. These results could provide insight 
into the pathogenesis of offspring health outcomes related to 
maternal HDP. The exploration of biologic pathways of the 
observed differential methylation must also consider the effect 
sizes detected in this study. Although statistically robust, the 
changes observed were in the range of 0.6% to 2.6%. The im-
pact of this modest magnitude of differential DNA methyl-
ation at a tissue or organ level and hence their influence on 
health outcomes is currently unknown. Further research on the 
functional relevance of methylation changes at specific sites is 
required to further elucidate this.
There are several strengths to our study, including a large 
sample size, control for variation of DNA methylation lev-
els between blood cells, and the ability to explore change in 
any cord blood differentially methylated sites as offspring 
age in 1 study. We were able to control for several poten-
tial confounders but as in any epidemiologic study, we can-
not be certain that residual confounding does not influence 
our results and this might be one reason for inflation in our 
EWAS results. The association between HDP and differen-
tial DNA methylation in cord blood may be because of any 
treatments used for HDP (rather than HDP per se). With 
moderate or severe hypertension, treatment may include 
β-blockers, and women with HDP may have their infant 
delivered early. We did not have information on medications 
to explore their potential role. The time between birth and 
processing of cord blood may impact DNA methylation, and 
it is possible that this may differ between those with and 
without HDP (eg, cesarean section may be more common in 
20 3065559 cg04632887 AVP AVP TSS200 0.013 0.0022 2.05×10−9 +++−++++−− 0.001052
20 9141615 cg09143713* PLCB4 PLCB4 5′UTR 0.0141 0.0026 5.32×10−8 +++?+++++− 0.3546
Confounders adjusted for are the following: maternal age (year), parity (nulliparous vs multiparous), maternal smoking status (no smoking in pregnancy, stopped 
smoking in early pregnancy, smoking throughout pregnancy), diabetes mellitus (no preexisting or gestational diabetes mellitus vs prepregnancy or gestational diabetes 
mellitus), maternal prepregnancy BMI (kg/m2), and child sex. The model was also adjusted for estimated cell counts and technical covariates. Bonferroni significant CpGs 
sorted based on CHR and position. ALSPAC indicates Avon Longitudinal Study of Parents and Children; BMI, body mass index; CHR, chromosome; CpG, CpG site; GenR, 
Generation R; GOYA, Genetics of Overweight Young Adults; HDP, hypertensive disorders of pregnancy; HS, healthy start; IOW, Isle of Wight; MoBa, Norwegian Mother 
and Child Cohort Study; PREDO, Prevention of Preeclampsia and Intrauterine Growth Restriction; and UTR, untranslated region.
*CpG: these CpGs were found to be Bonferroni significant in adjusted analyses only (ie, not in the unadjusted analyses); mapped gene: CpGs were annotated using 
Illumina genome coordinate; nearest gene: nearest genes were annotated within 10 Mb of each CpG as described41; gene group: University of California, Santa Cruz 
gene region feature category; Coef: difference in mean methylation at the CpG comparing HDP to no HDP in β-units (β-units are the proportion of cells at that CpG that 
are methylated; negative values indicate lower methylation in offspring exposed to HDP and positive higher methylation in those exposed); SE: SE of the difference in 
mean regression coefficient; P value: exact P value from statistical model; direction: direction of association for each cohort included in the meta-analysis; methylation: 
higher (+), lower (−), or the CpG was missing (?) in those whose mothers had HDP compared with those who did not. For direction of association, the order of cohorts is 
ALSPAC, GenR, Viva, IOW, HS–non-Hispanic, MoBa1, MoBa2, GOYA, PREDO, and HS-Hispanic. Cochran Q=Cochrane Q statistic to test heterogeneity.
Table 2. Continued
CHR Position CpG
Mapped 
Gene Nearest Gene Gene Group Coefficient SE P Value Direction Cochrane Q
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women with HDP and may influence the time from delivery 
to sample processing); we do not have information on this 
time interval to adjust for it.
In conclusion, we identified associations between both 
maternal HDP and preeclampsia and DNA methylation at sev-
eral loci across the genome in cord blood. Pathway analysis 
suggested that several of these CpGs are involved in devel-
opmental embryogenesis or neurological pathways. We also 
found overlap between HDP-related differentially methylated 
CpGs from our study and those found in EWAS of birth weight 
and gestational age, in directions that are consistent with asso-
ciations of HDP with these outcomes (eg, higher methylation 
at CpGs related to HDP being related to lower birth weight and 
shorter gestational age). However, the biologic and health rel-
evance of the relatively small mean differences in DNA meth-
ylation found in our EWAS is unclear, and further research, 
including the use of methods to distinguish causation from as-
sociation, is needed to fully understand our findings.
Perspectives
HDP including GH and preeclampsia is associated with ad-
verse offspring outcomes. Epidemiologic studies have found 
the associations between HDP and offspring health outcomes 
including a higher risk of cardiovascular disease. The mecha-
nisms underlying these associations are partly unclear but 
environmentally responsive; DNA methylation—a type of ep-
igenetic modification—may mediate the relationship between 
the genetic sequence, environmental factors, and offspring 
health outcomes. This study identified differences in cord 
blood methylation pattern with HDP. These findings begin to 
help us to understand the biologic processes that HDP may 
influence and possibly mechanisms by which HDP may effect 
offspring health outcomes.
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What Is New?
•	Epigenome-wide association studies were conducted to identify associa-
tions of hypertensive disorders of pregnancy (HDP; including gestational 
hypertension and preeclampsia) and preeclampsia with DNA methylation 
at CpG sites and regions in cord blood.
•	The study meta-analyzed participant samples (n=5242; 476 with HDP) 
from 10 independent birth cohorts from the pregnancy and childhood 
epigenetics consortium. To the best of our knowledge, this is the largest 
epigenome-wide association study of HDP and preeclampsia.
•	We performed novel longitudinal analysis to investigate the change in 
differentially methylated CpG sites identified in relation to HDP in cord 
blood from birth to 17 years of age using data from one of the cohorts 
(n=658; 108 with HDP).
What Is Relevant?
•	This study could identify novel epigenetic mechanisms that mediate ef-
fects of HDP on birth weight, gestational length, and future offspring car-
diovascular outcomes.
•	HDP-associated DNA methylation patterns may act as biomarkers of di-
sease or be modifiable targets for disease treatment in the future.
Summary
HDP including gestational hypertension and preeclampsia has 
been associated with shorter gestational age, lower birth weight, 
and subsequent cardiovascular diseases in women and their off-
spring. DNA methylation could be a potential mediator of these as-
sociations. This study found associations of HDP with differentially 
methylated CpG sites and regions across the genome in cord blood. 
It also found some evidence that these CpG sites are related to 
development, embryogenesis, and neurological outcomes. These 
findings may be relevant to associations of HDP adverse perinatal 
and later outcomes.
Novelty and Significance
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